Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

Table 3 Estimation of effectiveness against all-cause pneumonia for PCV13

	Proportion of all-cause pneumonia (%)	Assumed VE
19A	12%	23.4% × 1.13^‡
All other pneumonia	88%	23.4%
(Weighted) Total		23.8%
^‡ refer to calculation below
	PHiD-CV	PCV13
VE 19A IPD	71%	80%
VE ratio, (PCV13:PHiD-CV)	1.13

^‡Calculation of 1.13 as the VE ratio
IPD invasive pneumococcal disease, PCV13 13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, VE vaccine effectiveness

ISSN: 1478-7547